Physician profile
William Desimone
NPI 1831501949
$15,141.61
in general payments reported to CMS, 2019-2025
64 companies · $2,489 in 2025
The $2,489 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,514 · 2020: $1,364 · 2021: $2,109 · 2022: $1,372 · 2023: $2,497 · 2024: $2,796 · 2025: $2,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,782.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,698.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,971.78 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,152.83 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $1,140.15 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $1,091.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $971.37 | 2021-2025 | Linzess, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.53 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Amarin Pharma, INC. | $719.69 | 2019-2023 | |
| Glaxosmithkline, LLC. | $618.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $366.04 | 2019-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $356.67 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $290.62 | 2024-2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $282.84 | 2020-2025 | Seglentis, Livalo, Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.83 | 2020-2024 | Xifaxan |
| Pfizer INC. | $217.71 | 2020-2024 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Desimone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.